Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44009   clinical trials with a EudraCT protocol, of which   7316   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2008-005885-30
    Sponsor's Protocol Code Number:B1321001
    National Competent Authority:Bulgarian Drug Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2009-06-19
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBulgarian Drug Agency
    A.2EudraCT number2008-005885-30
    A.3Full title of the trial
    A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED,
    SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION
    A.4.1Sponsor's protocol code numberB1321001
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc., 235 East 42nd Street, New York, NY 10017
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Thelin
    D.2.1.1.2Name of the Marketing Authorisation holderEncysive (UK) Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/04/234
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSITAXSENTAN SODIUM
    D.3.9.1CAS number 210421-64-0
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pulmonary arterial hypertension
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 13.1
    E.1.2Level HLT
    E.1.2Classification code 10037401
    E.1.2Term Pulmonary hypertensions
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg dose) as compared to placebo in the treatment of subjects with PAH for 12 weeks, as determined by change from the Baseline 6MWD to Week 12.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to evaluate the safety and efficacy of sitaxsentan (100 mg dose) as compared to placebo in the treatment of subjects with PAH by determining change from Baseline in WHO functional class and time to clinical worsening.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all of the following inclusion criteria prior to study entry to be eligible for enrollment into the study:
    1.Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
    2.Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
    3.Has a current diagnosis of symptomatic PAH classified by one of the following:
    a.Idiopathic, or familial pulmonary arterial hypertension (IPAH or FPAH).
    b.PAH associated with one of the following connective tissue diseases:
    i.Systemic sclerosis (scleroderma).
    ii.Limited scleroderma.
    iii.Mixed connective tissue disease.
    iv.Systemic lupus erythematosus.
    v.Overlap syndrome.
    c.Exposure to legal drugs and toxins (eg, anorexigens, L-tryptophan, toxic rapeseed oil). Subjects with PAH caused by methamphetamine use are excluded.
    4.Has WHO functional class III symptoms.
    5.Is ≥16 and ≤80 years of age.
    6.Has 6MWT distances ≥150 and ≤450 meters and distance walked within 15% of one another on two consecutive tests on different days at Screening. Both tests must be ≥150 and ≤450 meters. If the test results are not congruent, both of the Screening 6MWT should be repeated 24 hours to 2 weeks after the first attempt and the results must be within 15% of one another. If after this attempt, the subject is still not eligible, the subject will be considered a screen failure and denied entry into the study.
    7.Had a ventilation-perfusion (V/Q) lung scan or spiral/helical/electron beam computed tomography (CT), or pulmonary angiogram within the 3 years prior to screening that shows no evidence of thromboembolic disease (i.e. should be normal or low probability for pulmonary embolism). If a V/Q scan is abnormal (i.e. is not normal or low probability), then a confirmatory CT, angiography or selective pulmonary angiography must exclude chronic thromboembolic disease.
    8.Had the diagnosis of PAH confirmed by a cardiac catheterization within 6 months prior to screening with the following values:
    a.Mean pulmonary artery pressure (mPAP) >25 mm Hg (at rest).
    b.Pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure ≤15 mm Hg; and
    c.Pulmonary vascular resistance (PVR) >3 mm Hg/L/min or 240 dynes*sec/cm5.
    9.If on calcium channel blockers, has been receiving a stable dose for at least 1 month prior to screening.
    10.If on vasodilators, digoxin, diuretics or spironolactone has been receiving a stable dose for at least 1 month prior to study screening.
    11.If on oxygen has been on a stable flow rate (two flow rates i.e. one at rest and one for exercise is permitted) for at least 1 month prior to study screening.
    12.If on corticosteroids, has been receiving a stable dose of ≤20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month prior to study screening. If receiving treatment for CTD with any other drugs, doses should remain stable for the duration of the study.
    13.If on any medication belonging to the statin drug class eg, lovastatin, atorvastatin, has been receiving a stable dose for at least 3 months prior to study screening and maintained throughout the study.
    14.If on warfarin (Coumadin®) or other vitamin K antagonists, has been receiving a stable treatment for at least 1 month prior to study screening; titration to target international normalized ratio (INR) is permitted.
    15.Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method), have a negative pregnancy test at Screening and Baseline/Day 1 and agree to use reliable methods of contraception for at least 1 month after the final study visit. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential.
    E.4Principal exclusion criteria
    Subjects presenting with any of the following will not be included in the study:
    1.Participation in other studies (with an investigational drug or device that has not received regulatory approval) within 30 days before the current study begins (screening) and/or during study participation.
    2.Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan or ambrisentan.
    3.Is taking, or has an anticipated need for systemic administration (oral, intravenous (IV)) of cyclosporine A for the duration of the study.
    4.Chronic treatment with PAH-specific drugs prior to the first day of study Screening or during the study with any of the following listed below. As this study is intended for subjects naïve to specific PAH treatment chronic treatment is defined as treatment administered for 30 days or longer.
    a.Any prostacyclin or prostacyclin analogue.
    b.Any phosphodiesterase-5 (PDE-5) inhibitor. The use of PDE-5 inhibitors as needed for erectile dysfunction is permitted as long as the subject has not taken a dose within 48 hours of an efficacy assessment. In addition, the subject should not take more than 8 sildenafil tablets, 6 vardenafil tablets or 4 tadalafil tablets per month.
    c.Intravenous inotropes, or
    d.Inhaled nitric oxide (excluding acute vasodilator testing during diagnostic cardiac catheterization).
    5.Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening.
    6.Has pulmonary function tests within 3 months prior to screening that reveal evidence of significant parenchymal lung disease. Parenchymal lung disease may be measured post-bronchodilator use and is defined as:
    a.Total lung capacity <70% (predicted), must be measured for CTD subjects
    b.Forced expiratory volume in 1 second (FEV1 ) ≤70% (predicted), or
    c.Forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) ≤60% (predicted).
    7.Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C).
    8.Has known human immunodeficiency virus (HIV) infection, under treatment with or has anticipated need for HIV specific antiretroviral therapy.
    9.Has hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 times the upper limit of the normal range or direct bilirubin >2 times the upper limit of the normal range at Screening or Baseline.
    10.Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at Screening or requires dialytic support.
    11.Has a hemoglobin concentration <10 g/dL at Screening.
    12.History of obstructive sleep apnea (treated or untreated).
    13.History of atrial septostomy.
    14.Has history of left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
    a.Repaired or unrepaired congenital heart disease (CHD).
    b.Aortic or mitral valve disease (stenosis or regurgitation) defined as more than minimum aortic insufficiency and more than moderate mitral regurgitation.
    c.Pericardial constriction.
    d.Restrictive or congestive cardiomyopathy.
    e.Left ventricular ejection fraction <40% by multiple gated acquisition scan (MUGA), angiography or echocardiography (ECHO).
    f.Left ventricular shortening fraction <22% by ECHO.
    g.Symptomatic coronary disease with demonstrable ischemia, or
    h.Evidence of left ventricular hypertrophy or diastolic dysfunction obtained by ECG or ECHO within 3 months prior to screening.
    Echocardiographic evidence of concentric remodeling and/or diastolic dysfunction is defined for example by left atrial diameter ≥4.5 cm or wall thickness of ≥11 mm within 3 months prior to screening.
    15.History of malignancy within 5 years prior to screening, with the exception of localized skin or cervical carcinomas.
    16.Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
    17.Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 30 days prior to study screening Day 1 and for the duration of the study.
    18.Is currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
    19.Is allergic to the ingredients of sitaxsentan or tablet excipients.
    20.Investigators, study staff or their immediate families.
    E.5 End points
    E.5.1Primary end point(s)
    The efficacy endpoint of change in 6-MWD will be measured at Baseline/Day 1 and Weeks 4, 8 and 12. The primary efficacy endpoint is the change in 6MWD at Week 12.
    The secondary efficacy endpoints of change in WHO functional class will be measured at Baseline/Day 1 and Weeks 4, 8 and 12 and the time to clinical worsening will be assessed and will be evaluated as the number of days between the first dose of study drug and the occurrence of a predefined clinical worsening event. The following will be considered clinical worsening events with confirmation by a blinded Adjudication Committee:
    •Hospitalization for worsening PAH (defined as hospitalization for at least 24 hours occasioned by a clinical condition clearly related to PAH such as right heart failure, arrhythmia, syncope, for intravenous diuretic or inotropic medications such as dobutamine, or for initiation of other PAH disease specific therapies)
    •On-study death
    •Heart-lung or lung transplant
    •Atrial septostomy, or
    •Withdrawal due to the addition of any of the following chronic medications for the treatment of worsening PAH: prostacyclin, prostacyclin analogues, phosphodiesterase-5 inhibitors, alternative endothelin receptor antagonists or intravenous inotropes
    •Initiation of oxygen for the treatment of worsening PAH
    The change from baseline to week 12 in NT-proBNP, SF-36 and EQ-5D will be assessed as exploratory endpoints.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA30
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    As per protocol
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 150
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2009-06-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-06-25
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2011-01-31
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA